141 related articles for article (PubMed ID: 34901300)
1. Ambulatory Fluoroquinolone Use in the United States, 2015-2019.
Umarje SP; Alexander CG; Cohen AJ
Open Forum Infect Dis; 2021 Dec; 8(12):ofab538. PubMed ID: 34901300
[TBL] [Abstract][Full Text] [Related]
2. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration.
Sankar A; Swanson KM; Zhou J; Jena AB; Ross JS; Shah ND; Karaca-Mandic P
JAMA Netw Open; 2021 Dec; 4(12):e2136662. PubMed ID: 34851398
[TBL] [Abstract][Full Text] [Related]
3. Current prescribing practices and guideline concordance for the treatment of uncomplicated urinary tract infections in women.
Langner JL; Chiang KF; Stafford RS
Am J Obstet Gynecol; 2021 Sep; 225(3):272.e1-272.e11. PubMed ID: 33848538
[TBL] [Abstract][Full Text] [Related]
4. Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings.
Buehrle DJ; Wagener MM; Clancy CJ
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0015121. PubMed ID: 33875430
[TBL] [Abstract][Full Text] [Related]
5. Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020.
Sarkar S; Heyward J; Alexander GC; Kalyani RR
JAMA Netw Open; 2021 Oct; 4(10):e2128782. PubMed ID: 34636912
[TBL] [Abstract][Full Text] [Related]
6. Outpatient Fluoroquinolone Use in Children, 2000-2018.
Ross RK; Gerber JS; Willis ZI; Hersh AL; Kinlaw AC
J Pediatric Infect Dis Soc; 2021 May; 10(5):576-585. PubMed ID: 33377490
[TBL] [Abstract][Full Text] [Related]
7. Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning.
Bratsman A; Mathias K; Laubscher R; Grigoryan L; Rose S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):701-707. PubMed ID: 32390266
[TBL] [Abstract][Full Text] [Related]
8. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators.
Maisel WH; Sweeney MO; Stevenson WG; Ellison KE; Epstein LM
JAMA; 2001 Aug; 286(7):793-9. PubMed ID: 11497532
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone prescribing in the United States: 1995 to 2002.
Linder JA; Huang ES; Steinman MA; Gonzales R; Stafford RS
Am J Med; 2005 Mar; 118(3):259-68. PubMed ID: 15745724
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002-2011.
Kobayashi M; Shapiro DJ; Hersh AL; Sanchez GV; Hicks LA
Open Forum Infect Dis; 2016 Sep; 3(3):ofw159. PubMed ID: 27704014
[No Abstract] [Full Text] [Related]
11. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
[TBL] [Abstract][Full Text] [Related]
12. Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.
Hartung DM; Middleton L; Markwardt S; Williamson K; Ketchum K
Clin Ther; 2015 Jan; 37(1):114-123.e1. PubMed ID: 25465946
[TBL] [Abstract][Full Text] [Related]
13. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.
Yarrington ME; Anderson DJ; Dodds Ashley E; Jones T; Davis A; Johnson M; Lokhnygina Y; Sexton DJ; Moehring RW
Infect Control Hosp Epidemiol; 2019 Nov; 40(11):1297-1300. PubMed ID: 31474240
[TBL] [Abstract][Full Text] [Related]
14. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012.
Almalki ZS; Alahmari AK; Guo JJ; Cavanaugh TM
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1042-51. PubMed ID: 27133913
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a pharmacist-led fluoroquinolone stewardship program: Improving use within the ambulatory care setting.
Portman DB; Pattison VM; Summerville AM
J Am Pharm Assoc (2003); 2020; 60(6):e312-e318. PubMed ID: 32595102
[TBL] [Abstract][Full Text] [Related]
17. Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection.
Shea KM; Hobbs ALV; Jaso TC; Bissett JD; Cruz CM; Douglass ET; Garey KW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348151
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study.
Daneman N; Chateau D; Dahl M; Zhang J; Fisher A; Sketris IS; Quail J; Marra F; Ernst P; Bugden S;
Clin Microbiol Infect; 2020 May; 26(5):613-618. PubMed ID: 31655215
[TBL] [Abstract][Full Text] [Related]
19. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
20. Black box warnings: what do they mean to pharmacists and patients.
Martin CM; Borgelt L
Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
